AERI

Rocklatan (Roclanda - EU) (netarsudil (ROCK - rho kinase inhib) & latanoprost (ophthalmic solution)

ophthalmology

Quarterly Sales (Approved)

Exp Date

Feb 2021 (est)

Amp Volatility Score

N/A

Catalyst Info & Data Links


TITLE: Rocklatan for ophthalmology (reduction in IOP) Quarterly Sales (Approved)

WHAT IS THE NEXT CATALYST EVENT?

  • Quarterly Sales (Approved)

  • MAA approval decision in Europe (MAA filed)

WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • February 20, 2021 (Est)

PRIOR DATA/EVENTS

PRESS RELEASES

  • Rhopressa® and Rocklatan® generated third quarter 2020 net revenues of $20.1 million, compared to $18.5 million in the third quarter of 2019, equivalent to an average of $77 per bottle, relatively consistent with the $78 per bottle in the second quarter of 2020. Shipments to wholesalers totaled 261,000 bottles during the third quarter of 2020, over 12 percent higher than the 232,500 bottles in the second quarter of 2020. Net revenues for the nine months ended September 30, 2020 totaled $58.5 million, compared to $45.2 million for the nine months ended September 30, 2019, reflecting a 29 percent increase.

  • Q3 '20 quarterly press release

  • 11-05-2021 Third Quarter Report


Publications or Posters 

PUBLICATIONS

  • Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2020.

  1. Asrani, S., Bacharach, J., Holland, E. et al. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2. Adv Ther 37, 1620–1631 (2020).

  2. Higginbotham E. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1-9

  3. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005 May;112(5):863-8.

  4. Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011 Jan;59 Suppl(Suppl1):S93-6.

  5. Glaucoma Research Foundation. National Glaucoma Patient and Caregiver Survey. September 5, 2019.

Rocklatan® is believed to utilize 2 outflow pathways to reduce IOP
Rocklatan® brings together the first-in-class rho kinase inhibitor, netarsudil, and market-leading prostaglandin, latanoprost, to help lower IOP with one drop.

Netarsudil
Netarsudil is a rho kinase (ROCK) inhibitor specifically designed to target the trabecular meshwork. It is believed to reduce IOP by increasing the outflow of aqueous humor.1,2Latanoprost
Latanoprost is a prostaglandin that is believed to reduce IOP by increasing the outflow of aqueous humor through the uveoscleral pathway.3

Rocklatan®
Rocklatan® is believed to utilize the mechanisms of action of Rhopressa® and latanoprost.1Lowers IOP significantly more than latanoprost1,4
Helps more patients reach lower target pressures1,4

EJV

Rocklatan, glaucoma, IOP, ophthalmology, netarsudil, rho_kinase_inhibitor, Latanoprost, ROCK, uveoscleral_pathway, aeri

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon